Steven Cohen Denali Therapeutics Inc. Transaction History

Point72 Asset Management, L.P.

$51 Billion
Q3 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 2,519,535 shares of DNLI stock, worth $43.9 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

2,519,535

Previous 2,213,947 13.8%

Holding current value

$43.9 Million

Previous $31 Million 18.11%

% of portfolio

0.07%

Previous 0.07%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$12.75 - $15.65 $3.9 Million - $4.78 Million	305,588 Added 13.8%	2,519,535 $36.6 Million
Q2 2025 Aug 14, 2025	BUY	$11.47 - $16.65 $25.4 Million - $36.9 Million	2,213,947 New	2,213,947 $31 Million
Q4 2024 Feb 14, 2025	BUY	$20.24 - $31.58 $4.36 Million - $6.8 Million	215,209 Added 64.52%	548,739 $11.2 Million
Q3 2024 Nov 14, 2024	SELL	$20.96 - $31.05 $15.1 Million - $22.3 Million	-719,620 Reduced 68.33%	333,530 $9.72 Million
Q2 2024 Aug 14, 2024	BUY	$14.96 - $23.22 $15.8 Million - $24.5 Million	1,053,150 New	1,053,150 $24.5 Million

Q4 2023 Feb 14, 2024	BUY	$16.2 - $23.18 $10.4 Million - $14.9 Million	644,406 New	644,406 $13.8 Million
Q2 2023 Aug 14, 2023	BUY	$23.37 - $32.96 $5.22 Million - $7.37 Million	223,471 New	223,471 $6.59 Million
Q1 2023 May 15, 2023	SELL	$21.91 - $32.67 $1.41 Million - $2.1 Million	-64,400 Closed	0 $0
Q4 2022 Feb 14, 2023	SELL	$26.28 - $33.92 $14.9 Million - $19.3 Million	-568,600 Reduced 89.83%	64,400 $1.79 Million
Q3 2022 Nov 14, 2022	BUY	$25.97 - $38.53 $16.4 Million - $24.4 Million	633,000 New	633,000 $19.4 Million

Others Institutions Holding DNLI

# of Institutions

259

Shares Held

133M

Call Options Held

219K

Put Options Held

107K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.34B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account